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Abstract
Background: The IgG autoantibody ANNA-2 (anti-Ri) is a type 2 antineuronal antibody that has
been found to bind to highly conserved and widely distributed adult brain proteins encoded by the
Nova-1 and Nova-2 genes. Anti-Ri antibodies are typically detected in the serum and cerebrospinal
fluids of patients with neurological disorders such as opsoclonus/myoclonus and cerebellar ataxia
and in association with gynecologic and breast malignancies.
Case Presentation: This report describes an unusual example of a 33-year-old female patient
who developed short-term memory deficits over a 3-month period. An extensive neurological
work-up, including a panel of paraneoplastic markers was negative with the exception of a high titer
serum Anti-Ri (1:15,3600). A large left ovarian mass was palpated, surgically resected and eventually
diagnosed as a mature cystic teratoma. Post-operatively, memory deficits had disappeared within 1
month and serum Anti-Ri titers had decreased significantly to 1:256. An extensive diagnostic work-
up for other malignancies was negative.
Conclusion: Although, Anti-Ri antibodies are typically associated with malignancies, this case
illustrates the potential association between benign tumors and this autoantibody.
Background
Paraneoplastic syndromes (PNS) are signs or symptoms
attributable to tissue damage at sites that are remote from
a primary malignancy or their metastases. PNS involving
virtually every level of the neuro-muscular system have
been described [1-3]. Typically, the paraneoplastic syn-
dromes causing neurologic disorders precede the diagno-
sis of the neoplasm and are often the main reasons that
medical attention is sought [2,3]. Recent attention has
thus centered on discovering novel serum or cerebrospi-
nal fluid markers that can specifically identify not only the
presence of a malignancy, but the type of malignancy
involved if present.
A wide variety of anti-neuronal antibodies have been
associated with the many PNS-associated neurologic dis-
orders [2]. These antibodies have varying degrees of sensi-
tivity and specificity for the underlying types of
malignancies. However, in the right setting, the presence
of a given auto-antibody in combination with specific
signs and symptoms, may reasonably predict the primary
site and tumor type. The vast majority of tumors associ-
ated with PNS-neurological disorders are malignant [2].
Notable exceptions include the identification of antibod-
ies to voltage gated potassium channels (VGKC) in
patients with thymomas [4]. We describe in this report the
finding of a common anti-neuronal antibody (anti-Ri) in
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a patient with a benign neoplasm: mature cystic teratoma
of the ovary, and whose neurologic symptoms, short-term
memory deficits, was apparently associated with her
tumor.
Clinical history
A 33-year-old nulligravid female with no significant past
medical history presented to her physician with com-
plaints of a short-term memory loss of approximately
three months' duration. This included an inability to
remember details about 24-hour old events. There had
been no major socio-economic or personal changes in her
life over this period. A detailed neurologic examination
was notable only for her presenting complaint. Routine
laboratory work-up, including a lumbar puncture were all
within normal limits. A physical examination revealed a
large right adnexal mass, which upon ultrasonographic
assessment showed internal features suggestive of a malig-
nancy. A panel of serum paraneoplastic autoantibodies
was then requested, including anti-Hu, anti-Yo, anti-Ri,
anti-Tr and anti-Ma1/2. All were normal with the excep-
tion of IgG anti-Ri, measured at 1:15,360 by an indirect
immunofluorescence method. An extensive diagnostic
work-up failed to reveal any malignancies. The patient
subsequently underwent a right salpingo-oophorectomy,
and her adnexal mass was diagnosed as a benign mature
cystic teratoma of the ovary. Almost immediately follow-
ing her surgery, the patient expressed a subjective
improvement in her symptoms. Within a month, the
serum anti-Ri had decreased to 1:256, and a detailed neu-
rologic examination revealed resolution of her symptoms.
She has not experienced any relapse in her symptoms in
the 1 year since her surgery.
Discussion
In 1988 and 1991, Budde-Steffen at al [5] and Luque et al
[6] described a subpopulation of patients with opso-
clonus and a history of breast cancer in whose serum and
CSF were identified an antibody that reacted against 55
kD and 80 kD proteins that were designated Anti-Ri (also
known as ANNA-2). It has since been shown that these
antigens are highly conserved but widely distributed cen-
tral nervous system neuronal proteins which are encoded
by the Nova-1 and Nova-2 genes and which may play a role
in neuronal maturation and homeostasis [7-9]. As those
seminal reports indicate, Anti-Ri was initially associated
with opsoclonus/myoclonus and cerebellar ataxia symp-
tomatology in patients with breast and gynecologic can-
cers. They have however subsequently been associated
with a wide variety of malignancies that have included
lung, gastric and bladder carcinomas [10]. Indeed, in one
study, 32% and 36% of cancers associated with anti-Ri in
patients with suspected PNS were breast and lung carcino-
mas respectively [10]. The spectrum of associated neuro-
logic symptoms has also expanded considerably and now
includes vertigo, muscle weakness, dysarthria, dysphagia,
dementia, deafness, myelopathy, opthalmoplegia,
encephalomyelitis, rigidity, nausea, myelopathy, sensori-
motor neuropathy [10]. What these cases illustrate is that
with a few exceptions [4], the vast majority of tumors
associated with PNS-neurological disorders are malig-
nant. Our case thus highlights the potential association
between a benign neoplasm and the presence of these
antibodies and neuronal symptomatology.
Is it possible that the presence of the autoantibody and the
ovarian tumor are completely fortuitous?. Given the tem-
poral relationship between the resolution of her symp-
toms and the sharp decrease in her anti-Ri titer following
her surgery, we believe this is unlikely. However, the pre-
cise mechanistic basis for this association as well as poten-
tial influence of outside factors remains to be elucidated.
It should also be noted that high titers of Anti-Ri have
been identified in patients with a history of ovarian cancer
but without any evidence of a PNS, suggesting caution in
assessing the specificity of this auto-antibody for PNS.
In summary, we describe in this report an association of a
common anti-neuronal antibody (anti-Ri) in a patient
with a benign neoplasm, mature cystic teratoma of the
ovary, and whose neurologic symptoms, short-term mem-
ory deficits, was apparently associated with her tumor.
Although, Anti-Ri antibodies are typically associated with
malignancies, this case illustrates the potential association
between benign tumors and this autoantibody.
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